Reconsidering current approaches to valve and LVAD therapies
Key topics:
-Epic Plus Mitral is a suitable platform for MICS delivering favourable outcomes – M. Loubani
-Better hemodynamic outcomes can be achieved with Epic Max – T. Holubec
-Surgical assessment and technical strategies to overcome more challenging patient characteristics when implanting LVADs – A. Loforte
-The impact of avoiding Aspirin in HeartMate 3 LVAD patients: results from the ARIES trial – I.Netuka